Mentice

Mentice Net Debt per Share

The Net Debt per Share of Mentice (MNTC.ST) as of Nov 19, 2026 is -0.59 SEK. In the previous year, Net Debt per Share was -1.58 SEK — a change of -62.76% (higher).

Net Debt per Share

-0.59SEK

YoY

-62.76%

Last updated:

Net Debt per Share of Mentice is 2025 -0.59 SEK. Net Debt per Share of Mentice was 2024 -1.58 SEK. It decreases by -62.76% higher compared to the previous year.

The Mentice Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-2.02 SEK
Jan 1, 2019
-1.16 SEK
Jan 1, 2020
-1.32 SEK
Jan 1, 2021
0.07 SEK
Jan 1, 2022
-1.09 SEK
Jan 1, 2023
-1.76 SEK
Jan 1, 2024
-1.58 SEK
Jan 1, 2025
-0.59 SEK
The Mentice Net Debt per Share history
YEARNet Debt per ShareYoY
-0.59SEK-62.76%
-1.58SEK-10.32%
-1.76SEK+61.92%
-1.09SEK-1,625.16%
0.07SEK-105.39%
-1.32SEK+14.27%
-1.16SEK-42.51%
-2.02SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mentice Stock analysis

What does Mentice do? Mentice AB provides software and hardware simulation solutions for endovascular therapies, targeting healthcare professionals and the medical device industry. The company's solutions are scientifically validated and designed to help users acquire, retain, and enhance procedural skills in neurovascular, cardiovascular, and peripheral interventions. Mentice AB generates revenue through the sale of its simulation products and related services, with key buyers including healthcare providers and medical device manufacturers. The company operates globally, serving clients across multiple healthcare segments that require advanced training tools for minimally invasive procedures. Mentice AB's business model focuses on delivering scientifically validated simulation tools that address skill development needs in complex medical procedures. The firm's product offerings cater to both healthcare institutions seeking to train staff and medical device companies requiring validation tools for their products. By specializing in endovascular therapy simulations, Mentice AB serves a niche market with high demand for precise procedural training solutions. The company's global presence allows it to reach clients in various regions seeking advanced medical simulation technology. The company's revenue streams come from the sale of simulation software and hardware systems alongside ongoing service contracts. Healthcare providers purchase these solutions to improve staff competency in endovascular procedures, while medical device manufacturers use them to validate device performance in simulated environments. Mentice AB's solutions are specifically developed for the medical device industry and healthcare providers, creating a dual revenue stream from both sectors. The firm's focus on scientifically validated tools ensures strong market positioning within specialized medical training segments. Mentice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mentice stock

Net Debt per Share of Mentice is -0.59 SEK in 2025.

Net Debt per Share of Mentice changed from -1.58 SEK to -0.59 SEK, representing a -62.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Mentice since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Mentice

All Key Metrics — Mentice